Last reviewed · How we verify

AM(LT)

Medecins Sans Frontieres, Netherlands · FDA-approved active Small molecule

am(lt) is a small molecule that works by interacting with a specific target in the body, but its exact mechanism is unknown.

am(lt) is a small molecule drug developed by Medecins Sans Frontieres, Netherlands, but its target, drug class, and approved indications are unknown. As a small molecule, it is a type of chemical compound that can be used to treat various diseases. However, due to the lack of information, its commercial status, safety considerations, and mechanism of action are also unclear. Further research is needed to understand the properties and uses of am(lt).

At a glance

Generic nameAM(LT)
Also known asLariam®, Roche
SponsorMedecins Sans Frontieres, Netherlands
ModalitySmall molecule
Therapeutic areaNeuroscience
PhaseFDA-approved

Mechanism of action

Imagine am(lt) as a key that fits into a lock in the body. When it binds to the lock, it can either turn it on or off, or change the way it works. However, without knowing what the lock is or how it works, it's hard to understand exactly how am(lt) works its magic.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: